While the prevalence and importance of RAS/RAF/PI3K activating mutations across a very broad spectrum of human cancer types is clear, we still lack understanding of whether CD40 regulation by the RAS/RAF/PI3K pathway broadly serves as an immune evasion/tolerance mechanism in tumor progression and response to therapy. This evidence concerns the gene CD40 and neoplasm.